U.S. Markets closed

Featured Company News - Zymeworks Enters Into License Agreement with Janssen Biotech to Develop and Commercialize Next Generation Bispecific Antibody Therapeutics

Research Desk Line-up: Intrexon Post Earnings Coverage

LONDON, UK / ACCESSWIRE / November 15, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Zymeworks Inc. (NYSE: ZYME), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=ZYME. The Company announced on November 13, 2017, that it has entered into a licensing agreement with Janssen Biotech, Inc., one of the pharmaceutical Companies of Johnson & Johnson, to develop and commercialize next generation bispecific antibody therapeutics. For immediate access to our complimentary reports, including today's coverage, register for free now at:


Discover more of our free reports coverage from other companies within the Biotechnology industry. Pro-TD has currently selected Intrexon Corporation (NYSE: XON) for due-diligence and potential coverage as the Company announced on November 09, 2017, its financial results for Q3 2017. Tune in to our site to register for a free membership, and be among the early birds that get our report on Intrexon when we publish it.

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on ZYME; also brushing on XON. Go directly to your stock of interest and access today's free coverage at:



Terms of Licensing Agreement

  • Janssen Biotech will obtain a worldwide, royalty-bearing license from Zymeworks to research, develop, and commercialize up to six bispecific antibodies directed to Janssen Biotech's therapeutic targets using Zymeworks' Azymetric™ and EFECT™ platforms. The former will be responsible for all research, development, and commercial activities.
  • Janssen Biotech will be liable to make an upfront payment of US$50 million to Zymeworks, potentially climbing up to US$282 million in development and up to US$1.12 billion in commercial milestone payments, and tiered royalties on potential sales.
  • As per the agreement, Janssen Biotech also has the option to develop two additional bispecific programs under the agreement subject to a future option payment.

Collaboration to be Primarily Used to Fund Clinical Advancement of ZW25

Dr. Ali Tehrani, President and Chief Executive Officer (CEO) of Zymeworks, stated that the Company is very pleased to be partnering with Janssen Biotech and their world-class scientists, marking Zymeworks' sixth major pharmaceutical partnership and the first since its wholly-owned bispecific product candidate ZW25, which is enabled with the Azymetric™ platform, entered clinical trials. Tehrani added that the proceeds from this collaboration will be primarily used to fund the clinical advancement of ZW25, as well as the advancement of the Company's preclinical programs into the clinic.

Zymeworks Licensing Deal with Merck

On September 19, 2017, Merck provided formal notification of their plans to advance a bispecific drug candidate into preclinical development. The drug candidate was developed by Merck, through a subsidiary, in collaboration with Zymeworks, using Zymeworks' proprietary Azymetric™ and EFECT™ platforms as part of an existing Research and License Agreement between the two Companies. As per the terms of the Research and License Agreement, Zymeworks granted Merck a worldwide, royalty-bearing license to research, develop, and commercialize certain bispecific therapeutic candidates toward Merck's therapeutic targets.

About Azymetric™ and EFECT™ Platforms

The Azymetric™ platform enables the transformation of monospecific antibodies into bispecific antibodies, which gives them the ability to simultaneously bind two different targets. The EFECT™ platform is a library of antibody Fc modifications engineered to modulate the activity of the antibody-mediated immune response, which includes both the up- and down-regulation of effector functions.

About Zymeworks Inc.

Founded in 2003, Zymeworks is a clinical-stage biopharmaceutical Company that develops best-in-class Azymetric™ bispecific antibodies and antibody-drug conjugates for the treatment of oncology, autoimmunity, and inflammatory diseases. The Company's lead product candidate, ZW25, is a novel bispecific antibody currently being evaluated in an adaptive Phase-1 clinical trial. Zymeworks is headquartered in Vancouver, Canada.

About Janssen Biotech, Inc.

Established in 1992, Janssen Biotech is a biopharmaceutical Company specializing in the development and commercialization of therapeutic products for patients and the healthcare community. The Company operates as a subsidiary of Johnson & Johnson.

Last Close Stock Review

At the closing bell, on Tuesday, November 14, 2017, Zymeworks' stock climbed 2.10%, ending the trading session at $8.75. A total volume of 121.87 thousand shares have exchanged hands, which was higher than the 3-month average volume of 14.18 thousand shares. The Company's stock price surged 14.53% in the last three months. The stock currently has a market cap of $225.93 million.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter-holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.


For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily